Owner Scorecard


← All companies ← TAP Manual TASK → ← STRO Biotechnology TECH →

TARS, Tarsus Pharmaceuticals Inc.

Biotechnology consumer brand UnprofitableDistress / turnaroundNet current asset value

We are a commercial stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care.

TP-03 Demodex blepharitis in patients with Meibomian Gland Disease (MGD) MGD is commonly characterized by functional and structural dysfunction of the meibomian glands within the eyelid margin, leading to blockage and/or thickened, decreased meibum production.

Latest annual: FY2025 10-K
TARS · Tarsus Pharmaceuticals Inc.
I

The business

What it sells, where the money comes from, the kind of company it is.

Revenue · FY2025
$451M
+146.7% YoY
Vital signs · TTM, with 5-yr average
Revenue $606M 5-yr avg $147M
Operating margin −8.0% 5-yr avg −233.3%
ROIC −18% 5-yr avg −1547%
Owner-earnings margin 12% 5-yr avg −182%
Free cash flow margin 9% 5-yr avg −184%

Next report By 11/8 · the 10-Q for the quarter ended late September · due within 40 days of period end · has filed ~37 days after · the wire records it on arrival

The business in brief

read the 10-K →

What this business is and what moves its needle, from its own SEC filings.

Situation
Unprofitable. No sustained operating profit across the record; an earnings multiple has nothing to rest on. What the record does show is revenue, the gross-margin trajectory, and the burn against the cash on hand. Distress / turnaround. Thin interest coverage, or operating cash burned against real debt, across the record. The balance sheet carries this situation; the debt schedule sets the clock. Net current asset value. Current assets alone exceed every liability combined, and the surplus is most of the balance sheet: the shape Graham called a net-net.
What moves the needle
Operating margin has run around −66% through the cycle, the operating line deeply negative — so the lever is the path to a margin at all: revenue growth against the cost curve and the cash runway, not the level of a margin that isn't there yet. Stock-based pay runs about 15% of sales, a real and recurring claim on owners that the GAAP margin understates. Read this kind of business on the pipeline against the patent cliff, and pricing. On its own account, the filing leans hardest on pricing power & competition, set against the numbers in what the filing emphasizes, below.
Is it a good business?
Return on capital has rarely cleared the cost of capital (median −41%, above 15% in 0 of 4 years). Owner earnings, the cash-based check, have been thin too. This is price-taker territory, where the balance sheet and the cycle matter more than any multiple; the rest is in the 10-K.

Every line is arithmetic on the company's filings, shown in full in the sections below.

II

The record

Ten years of arithmetic, read across the cycle.

The record, 2020–2025

realized figures from each filing · older years to the left
2020’202021’212022’222023’232024’242025’25TTMTTMJun 2026
Income statement
$0$57M$26M$17M$183M$451M$606MRevenueRevenue
45%174%623%130%95%87%SG&A / revenueSG&A/rev
73%165%288%29%14%14%R&D / revenueR&D/rev
($27M)($12M)($63M)($143M)($121M)($71M)($49M)Operating incomeOp. inc.
−21.3%−242.9%−820.5%−65.9%−15.7%−8.0%Operating marginOp. mgn
($27M)($14M)($62M)($136M)($116M)($64M)Pretax incomePretax
($27M)($14M)($62M)($136M)($116M)($66M)($46M)Net incomeNet inc.
Cash flow & returns
($21M)$4M($49M)($117M)($83M)($12M)$74MOperating cash flowOp. cash
$100K$300K$326K$744K$685K$855K$1MDepreciationDeprec.
$5M$9M($725K)($2M)$4M$11M$67MWorking capital & otherWC & other
$456K$586K$506K$2M$2M$10M$18MCapexCapex
1.0%2.0%8.6%0.9%2.2%3.0%Capex / revenueCapex/rev
($21M)$3M($49M)($118M)($84M)($13M)$73MOwner earningsOwner earn.
6.0%−191.2%−677.7%−45.8%−2.9%12.0%Owner earnings marginOE mgn
($22M)$3M($50M)($119M)($85M)($22M)$56MFree cash flowFCF
5.5%−191.9%−682.0%−46.2%−4.9%9.2%Free cash flow marginFCF mgn
($456K)($586K)($145M)$141M($199M)($42M)Investing cash flowInv. cash
$132M$21K$94M$130M$155M$143MFinancing cash flowFin. cash
$110M$3M($100M)$153M($128M)$89MChange in cashΔ cash
-35%-6080%-47%-24%-18%ROICROIC
-16%-8%-32%-69%-51%-19%-13%Return on equityROE
−16%−8%−32%−69%−51%−19%−13%Retained to equityRetained/eq
Balance sheet
$168M$172M$217M$227M$291M$417M$450MCash & investmentsCash+inv
$0$17M$47M$85M$96MReceivablesReceiv.
$0$3M$3M$4M$4MInventoryInvent.
$18M$9M$16M$40MAccounts payablePayables
$0$2M$40M$73M$60MOperating working capitalOper. WC
$171M$176M$225M$256M$357M$523M$562MCurrent assetsCur. assets
$5M$11M$15M$37M$81M$136M$176MCurrent liabilitiesCur. liab.
31.7×15.3×14.6×6.9×4.4×3.9×3.2×Current ratioCurr. ratio
$548K$755K$957K$1M$2M$12MNet PP&ENet PP&E
$172M$179M$228M$265M$377M$562M$611MTotal assetsAssets
$0$19M$30M$72M$72M$73MTotal debtDebt
($172M)($198M)($198M)($220M)($345M)($377M)Net debt / (cash)Net debt
-28.5×-42.8×-15.4×-7.9×-5.5×Interest coverageInt. cov.
$6M$12M$35M$69M$152M$219MTotal liabilitiesTotal liab.
$166M$167M$193M$197M$225M$343M$347MShareholders’ equityEquity
14.8%52.1%113.7%15.2%9.2%8.5%Stock comp / revenueSBC/rev
Per share
6.2M20.6M24.6M29.4M37.6M41.8M43.2MShares out (diluted)Shares
$0.00$2.77$1.05$0.59$4.87$10.80$14.04Revenue / shareRev/sh
$-4.32$-0.67$-2.52$-4.62$-3.07$-1.59$-1.08EPS (diluted)EPS
$-3.42$0.17$-2.00$-4.02$-2.23$-0.32$1.69Owner earnings / shareOE/sh
$-3.48$0.15$-2.01$-4.05$-2.25$-0.53$1.30Free cash flow / shareFCF/sh
$0.07$0.03$0.02$0.05$0.04$0.24$0.42Cap. spending / shareCapex/sh
$26.74$8.11$7.84$6.70$5.97$8.22$8.03Book value / shareBVPS

The diluted share count moved ×3.31 into 2021 — shares issued, not a split the totals corroborate — and the per-share figures carry the counts as filed.

Per-share growththe realized rate an owner's share compounded
5-yr5-yr
Capital spending / share+26.3%/yr+26.3%/yr
Book value / share−21.0%/yr−21.0%/yr

Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.

In fiscal 2025 the business earned ($13M) of owner earnings, the operating cash left after the $855K it takes just to hold its position. It put $9M more into growth; free cash flow, after that spending, was ($22M).

FY2025FY2024FY2023FY2022FY2021
Reported net income($66M)($116M)($136M)($62M)($14M)
Depreciationnon-cash charge added back+$855K+$685K+$744K+$326K+$300K
Amortization of intangible assetsnon-cash charge added back; the purchase price of past acquisitions, expensed over time+$961K+$540K+$133K
Stock-based compensationreal costnon-cash, but a real cost+$42M+$28M+$20M+$13M+$8M
Working capital & othertiming of cash in and out, other non-cash items+$10M+$3M−$2M−$725K+$9M
Cash from operations($12M)($83M)($117M)($49M)$4M
Maintenance capital expenditurethe spending needed just to hold position and volume−$855K−$685K−$744K−$326K−$300K
Owner earnings($13M)($84M)($118M)($49M)$3M
Growth capital expenditurediscretionary; spent to get bigger, not to stand still−$9M−$882K−$758K−$180K−$286K
Free cash flow($22M)($85M)($119M)($50M)$3M
Owner-earnings marginowner earnings ÷ revenue-3%-46%-678%-191%6%

Owner earnings is the cash an owner could pull out without starving the business: operating cash less the maintenance capital it must spend to hold its position (here about $855K, roughly its depreciation, the rate its assets wear out). The other $9M of its capital spending is growth it chose, not upkeep it owed; charged only with the maintenance it must do, the business earns well more than the year's free cash flow shows. The cash-flow statement also adds stock comp back as non-cash, but it is a real cost paid in shares; counted as the expense it is (less $42M), owner earnings is nearer ($55M).

Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.

Dashed amortization years: the filer did not tag the intangible-amortization line that year, so that year's charge remains inside "Working capital & other."

III

Quality & stewardship

Returns, the balance sheet, capital allocation, and pay.

Owner’s Scorecard

FY2025 10-K · source on SEC EDGAR →

Will it survive?

  • Does not cover its interest
    Operating income ($71M) ÷ interest expense $9M
    What this means

    A full year of operating profit didn't cover the interest bill. This is the zombie zone: the business depends on refinancing, asset sales, or forbearance to service its debt.

  • Net cash
    Cash $184M + ST investments $234M − debt $72M
    What this means

    Cash and short-term investments exceed every dollar of debt by $345M, on net the company owes nothing, and can act from strength when others can't. Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.

  • Not enough data
    What this means

    The filing data didn't include the inputs for this check.

Is it a good business?

  • Below average through the cycle
    4-yr median, range -6080%–-24%; -24% latest = NOPAT ($56M) ÷ invested capital $232M
    Industry peers: median -35%
    What this means

    The rate the business earns on the money tied up in it, Buffett's north star, because over time a stock tracks the ROIC beneath it. Above ~15% sustained hints at a moat; a return below the cost of capital (~8%) erodes value as a business grows rather than building it — the test Buffett weighs most. The headline is the median of the last 4 years (it ran -24% most recently), so one peak or trough year doesn't set the verdict. Asset-light businesses (R&D expensed, little capital) read artificially high, pair this with Owner Earnings.

  • Consumes cash through the cycle
    5-yr median margin, range -678%–6%; latest ($13M) = operating cash ($12M) − maintenance capex $855K
    Industry peers: median -92%
    What this means

    What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's -3% of revenue this year, a -46% median across 5 years. It chose to put $9M more into growth, so free cash flow this year was ($22M) — the gap is investment, not weakness. Treating stock comp as the real expense it is (less $42M of SBC) leaves ($55M).

  • Loss, and burning cash
    Net income ($66M) · cash from operations ($12M)
    What this means

    The company reported a net loss, so a conversion ratio isn't meaningful. What matters then is whether operations still threw off cash, here, they did not.

How is the cash used?

  • Not enough data
    What this means

    The filing data didn't include the inputs for this check.

  • Investing or harvesting? 11.53×
    Expanding
    Capex $10M ÷ property depreciation $855K
    What this means

    Descriptive, not a grade. Above ~1× means investing faster than assets wear out (growth, or, sustained for years, today's earnings carrying less depreciation than tomorrow's will). Below means spending less than it's wearing out (efficiency, or a melting asset base). The ratio won't tell you which; the filings will.

The promise and the pay packet

  • Is the buyback buying ownership, or mopping up? 9.2%
    The count is rising
    Stock compensation $42M (fiscal 2025), 9.2% of revenue · no repurchases · diluted shares +69.7% since 2022
    What this means

    Stock handed to employees is a real cost paid in the owner's own currency: it is charged against profit, but the shares it creates are permanent. Many companies repurchase stock at the same time, which looks like a return of capital and often is not — if the count barely moves, the cash merely cancelled the pay packet and bought the owner nothing. The three states worth telling apart are a count genuinely shrinking, a count standing still despite large repurchases, and a count rising because the issuance was never offset at all.

Graham’s defensive tests · 2 of 4 met

Graham’s numerical criteria for the defensive investor (The Intelligent Investor, ch. 14), run on the filings. A floor of safety, not a buy signal; many fine modern businesses fail his strictest liquidity rules by design.

  • Adequate size Miss
    Revenue ≥ $2B · $451M
    What this means

    Big enough to weather a storm. Graham's 1972 floor was ~$100M of sales (≈ $700M today); we use a $2B revenue line as a conservative modern stand-in.

  • Strong liquidity Pass
    Current ratio ≥ 2× · 3.85×
    What this means

    Current assets at least twice current liabilities, near-term bills covered without touching the business. Strict by design: many cash-rich modern firms run leaner and miss it, holding their cushion in longer-dated securities.

  • Conservative debt Pass
    Debt ≤ working capital · $72M vs $387M WC
    What this means

    Graham's rule that borrowings not exceed net current assets. Capital-heavy and buyback-heavy firms routinely fail it, read it next to interest coverage, not alone.

  • Earnings stability Miss
    A profit every year (6-yr record) · 6 loss years
    What this means

    Graham wanted earnings in each of the past ten years, the stability a defensive owner leans on.

  • Dividend record
    Uninterrupted dividends · no dividend line tagged in the data
    What this means

    An unbroken dividend was Graham's mark of durability. This record carries no dividends-paid line in any year — common for partnerships, whose distributions file under tags the chain doesn't read — so the criterion is withheld rather than judged on silence.

  • Earnings growth
    Earnings +33% over the record ·
    What this means

    Earnings were negative early in the record, a growth rate isn't meaningful.

  • Moderate price
    P/E ≤ 15 and P/E × P/B ≤ 22.5 · decided by the price
    What this means

    Graham's valuation gate, the wall he kept between a sound business and a sound investment. Three-year average earnings are $-2.41/share (latest year $-1.51), the averaged base the calculator's gate runs on, and book value is $7.83/share. Enter a price in “What the price implies” just below for the P/E, P/B, and whether it clears. But this is the rule Buffett outgrew: there's no hard P/E law, and a wonderful business can deserve a far richer multiple if the thesis holds, treat it as the bargain-hunter's floor, not a verdict on the price.

Durability & moat, 2020–2025

Whether the record’s returns held, and what the capital reinvested earned.

  • Profitable years 0 of 6
    What this means

    Lost money in 6 year(s), look at what happened there before trusting the average.

  • Return on capital ≥ 15% 0 of 4 yrs
    What this means

    A moat shows up as a high return on invested capital that holds year after year, not one good vintage.

  • Operating margin −132% → −41% (2-yr avg ends)
    What this means

    Through the cycle the operating margin widened — about −132% early to −41% lately, median −66% — pricing power intact or improving.

  • Reinvestment, incremental ROIC returns capital
    What this means

    The capital base barely grew: this business returns cash through dividends and buybacks rather than reinvesting. Judge it on the cash returned, not on compounding.

  • Worst year 2023 · −820.5% op. margin
    What this means

    Operations went underwater in 2023, understand why before trusting the good years.

All figures as filed; the source filing is linked above.

Current Position

as of the latest quarter, Jun 30, 2026

Can the business pay what it owes this year, off the freshest balance sheet: the quality of the assets, the debt actually coming due, and what a low ratio means here.

Current assets$562M
  • Cash & short-term investments$450M
  • Receivables$96M
  • Inventory$4M
  • Other current assets$12M
Current liabilities$176M
  • Accounts payable$40M
  • Other current liabilities$136M
Current ratio3.20×all current assets ÷ what's due · Graham looked for 2×
Quick ratio3.17×stricter: inventory excluded
Cash ratio2.56×strictest: cash alone against what's due
Working capital$386Mthe cushion left after near-term bills
Revenue, latest quarter vs. a year ago+69.4%the freshest read on whether the business is still growing
Current ratio, recent quarters5.4× → 3.2×
Deeper floors
Tangible book value$340Mequity stripped of goodwill & intangibles
Net current asset value$298MGraham's net-net: current assets less all liabilities
Debt incl. operating leases$89M$16M of it operating leases

From the company's latest filing.

Management, ownership & pay

read the proxy →

From the proxy: how much of the business the people running it own, and how they are paid, beside what the business earned for its owners in the same years.

Fiscal yearChief executivePay, as filed“Actually paid”Owner earnings
2023Bobak Azamian$3.1M$4.5M($118M)
2024Bobak Azamian$7.9M$19.8M($84M)
2025Bobak Azamian$6.6M$31.1M($13M)

Both pay figures are the company’s own, from the pay-versus-performance table its proxy statement files. “As filed” is the Summary Compensation Table total: salary, bonus, and equity awards at their value on the day of grant. “Actually paid” is the SEC’s prescribed recalculation, which re-marks those equity awards to what they became as they vested; it can swing far above or below the filed figure in either direction, and negative years occur. Owner earnings are the whole business's, from the record above, for the same fiscal years.

  • Insider ownership9.6%

    The stake all directors and executive officers hold together, per the 2026 proxy: skin in the game, the first thing Munger reads.

  • CEO pay ratio26:1

    What the chief earns for every dollar the median employee makes, per the 2026 proxy. A high ratio alone settles nothing; some businesses are genuinely top-heavy in scarce skill. A runaway figure is where Buffett starts asking whether the board is doing its job.

  • Stock-based compensation$42M

    The slice of the business handed to employees in shares in fiscal 2025, 9.2% of revenue. Buffett's oldest accounting fight: this is compensation, compensation is an expense, real whether or not the headline earnings admit it. One trap: the cash-flow statement adds SBC back, so the operating cash, and the owner earnings drawn from it, are flattered by exactly this amount; counted as the cost it is, what an owner keeps is lower.

Peers, Biotechnology

The same industry, side by side on owner economics. Each column names the period it is read over, and a median resting on fewer than three years carries that count beside it; the group median at the foot is the line to read each figure against.

CompanyRevenuelatest FY, USDGross marginmedian over the recordOp. marginmedian over the recordROICmedian over the recordOwner earn. marginmedian over the record
RGENRepligen Corporation$738M55%13.4%4%12%
ALVOAlvotech$586M41%-297.3%-65%-246%
ADMAADMA Biologics Inc$510M-13%-106.6%-39%-158%
TARSTarsus Pharmaceuticals Inc.$451M-65.9%-41%-46%
IMCRImmunocore Holdings plc$400M99%1y-23.3%-2%
KRYSKrystal Biotech$389M22.6%-21%41%
TWSTTwist Bioscience Corporation$377M38%-115.4%-51%-92%
ADPTAdaptive Biotechnologies Corporation$277M68%-108.0%-32%-97%
Group median-86.3%-39%-69%
IV

The price

What a price has to assume.

What the price implies

reverse-DCF

Type today's close and see the owner-earnings growth you'd have to believe to justify it, beside what Tarsus Pharmaceuticals Inc. has delivered.

$
Base

The assumptions

9.0% = the 4.71% 10-year Treasury (Aug 18, 2026) + 4.29 points of equity premium. The rate you require is yours to set.

Enter a price above to run it.

Implied by the price
Owner-earnings growth, delivered
Owner-earnings yield
P/E (3-yr earnings ’23–’25)
P/B
Graham’s price gate

Graham capped the multiple at 15×; Buffett and Munger let that rule go: a wonderful business can deserve 50× if the thesis holds. The gate marks the bargain-hunter's floor.

Against a high-grade bond: Graham’s yardstick bond yield%

Prefilled with the 10-year Treasury (4.71%, as of Aug 18, 2026). Edit it for today’s exact figure, or a AAA corporate yield.

Graham measured a stock against the bond you could own instead, the heart of his margin of safety. Enter a price above to weigh the owner-earnings yield against this bond.

Free cash flow $56M on 44M shares outstanding, per the 10-Q cover, as of 2026-07-30; net cash $377M. The base is the latest year by default; Normalize values it on the through-cycle median owner-earnings margin (to avoid paying on a peak year). Net of stock comp treats option pay as the expense it is. Capex ($18M) runs well above depreciation ($1M), so this is a build-out; Steady-state swaps total capex for maintenance (≈ depreciation), lifting the base to about $73M, the cash it would throw off if it stopped expanding. The dials set the multiple a growth belief justifies; the price, and every dollar on this page, is yours.

Cite: Owner Scorecard, "Tarsus Pharmaceuticals Inc. (TARS), the owner's record," https://ownerscorecard.com/c/TARS, data as of 2026-08-17.

Manual order: ← TAP its page in the Manual TASK →

Industry order: ← STRO the Biotechnology chapter TECH →